Resource Summary Report

Generated by dkNET on Sep 6, 2026

624-mel

RRID:CVCL_8054
Type: Cell Line

Proper Citation

RRID:CVCL_8054

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8054

Proper Citation: RRID:CVCL_8054

Description: Cell line 624-mel is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: PMID:8027550, PMID:8081556, PMID:8537970, PMID:9759882, PMID:10048982, PMID:10754339, PMID:15467732, PMID:15592718, PMID:19340423, PMID:23851445, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27600516

Comments: From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 624-mel

Synonyms: 624-MEL, 624 MEL, 624 Mel, 624 mel, 624mel, 624MEL, 624, Mel-624, Mel624, MEL624

Cross References: BTO:BTO_0002951, EFO:EFO_0006359, ArrayExpress:E-MTAB-2706, BioGRID_ORCS_Cell_line:754, BioSample:SAMN03471309, cancercelllines:CVCL_8054, CGH-DB:9301-4, ChEMBL-Cells:CHEMBL3885941, Cosmic:876683, Cosmic:905214, Cosmic:1303044, Cosmic:1559441, Cosmic:2163793, EGA:EGAS00001000610, EGA:EGAS00001002554, ESTDAB:ESTDAB-049, GEO:GSM206438, GEO:GSM274692, PharmacoDB:624mel_23_2019, PubChem_Cell_line:CVCL_8054, Wikidata:Q54604356

ID: CVCL_8054

Record Creation Time: 20220427T215057+0000

Record Last Update: 20260905T184335+0000

Ratings and Alerts

No rating or validation information has been found for 624-mel.

No alerts have been found for 624-mel.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Franken GA, et al. (2026) Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma. Molecular oncology.

S??varsson T, et al. (2026) Enhanced IFNy response in dedifferentiated melanoma cells is due to chromatin remodeling as revealed by ATAC-seq. Cell communication and signaling : CCS, 24(1).

van Eck van der Sluijs J, et al. (2026) Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. Oncoimmunology, 15(1), 2649988.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. Cancer research, 86(11), 2688.

Allard D, et al. (2025) Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis. Cancer research, 85(4), 692.

Zhang Y, et al. (2025) A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell reports, 44(12), 116675.

Greiner D, et al. (2025) Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. Oncogene, 44(22), 1665.

Alsubaiti A, et al. (2025) Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable in vitro model of exhaustion. Immunotherapy advances, 5(1), ltaf023.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer immunology research, 12(10), 1421.

Becker AMD, et al. (2024) Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. Cell reports. Medicine, 5(2), 101386.

Wenthe J, et al. (2023) Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. Journal of translational medicine, 21(1), 506.

Sun R, et al. (2023) ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation. Cell chemical biology, 30(7), 739.

Kenski JCN, et al. (2023) An adverse tumor-protective effect of IDO1 inhibition. Cell reports. Medicine, 4(2), 100941.

Immisch L, et al. (2023) Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. Frontiers in immunology, 14, 1119498.

Dolton G, et al. (2023) Targeting of multiple tumor-associated antigens by individual T??cell receptors during successful cancer immunotherapy. Cell, 186(16), 3333.

Margolis N, et al. (2022) Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. Cancer immunology research, 10(9), 1127.

Huang L, et al. (2021) Targeting Pan-ETS Factors Inhibits Melanoma Progression. Cancer research, 81(8), 2071.

Creelan BC, et al. (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nature medicine, 27(8), 1410.

Willimsky G, et al. (2021) In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo. eLife, 10.